Company news
Cleo Diagnostics Ltd (ASX:COV) news
Every Cleo Diagnostics Ltd press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Appendix 4E and 2026 Annual Report
August 20, 2026
CLEO Enters Analytical Validation Phase
July 12, 2026
CLEO Establishes U.S. Reimbursement Pathway
May 19, 2026
CLEO Commences Kit Manufacturing Ahead of FDA Submission
April 27, 2026
Sample Collection Completion for Pivotal US Clinical Trial
March 30, 2026
CLEO Optimises Biomarker Panel Ahead of FDA Submission
March 22, 2026
Appendix 4D and Half Yearly Accounts
February 25, 2026
CLEO Confirms Next-Gen Platform for Ovarian Cancer Test
February 17, 2026
Quarterly activities and cashflow report
January 28, 2026
CLEO Raises $5m to Support U.S. Market Launch
December 17, 2025
Trading Halt
December 16, 2025
Cleo Strengthens Cash Position with $1.7m R&D Tax Refund
November 25, 2025
CLEO Appoints First Key Opinion Leader to Support US Market
November 18, 2025
CLEO Significantly Expands Addressable Market
November 5, 2025
CLEO Successfully Completes Stage 1 MDSAP Audit
October 29, 2025
Cleo Receives Positive FDA Feedback
September 14, 2025
Appendix 4E and 2025 Annual Report
August 26, 2025
COV Commences Health Economic Study-Support US Market Entry
August 17, 2025
CLEO Strengthens FDA Submission - Access to US Biobank
June 25, 2025
Corporate Presentation
June 11, 2025
Cleo Advances with Completion of Alpha Testing
May 12, 2025
CLEO to Fast Track Development of Ovarian Cancer Test
April 27, 2025
CLEO Receives A$845k Research and Development Tax Incentive
April 24, 2025
CLEO Delivers Commercial Development Milestone
March 17, 2025
Price Query Response
February 7, 2025
CLEO Further Expands Ovarian Cancer Trial with Siles Health
December 9, 2024
The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial
November 26, 2024
Cleo Commences U.S. Clinical Trials
September 5, 2024
Appendix 4E and 2024 Annual Report
August 27, 2024
CLEO Selects U.S. Clinical Trial Sites
July 30, 2024
Cleo Commences US Regulatory Process with FDA
June 25, 2024
COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
May 28, 2024
COV Appoints CRO to Manage US Ovarian Cancer Clinical Trials
April 10, 2024
CLEO Appoints Partner to Commence U.S. Market Access Program
April 2, 2024
Peer-Review Supports CLEOs Ovarian Cancer Detection Tech
March 24, 2024
Cleo Completes Design Transfer
February 11, 2024
Completion of First Triage Test Clinical Validation Study
November 5, 2023
Pause in Trading
November 2, 2023
Cleo Delivers Early Progress on Development Program
October 8, 2023
Appendix 4E and Preliminary Financial Report
August 31, 2023